Jul. 2 at 4:28 AM
$NAGE Remember UBX (Unity Biotherapeutics) and its promising anti-senolytic drugs? It was once discussed fairly intensively on the CDXC Yahoo site. Six years ago, it traded for as high as
$200 SP. I took a realized loss of
$125,000 when its SP went from about
$11 to
$4 when its knee arthritis trial failed. I put the remnant into CDXC (NAGE). UBX then kept chugging along with macular degeneration trials, and had early-stage success, but it ran out of money, and never generated a nickel in sales. Its assets will likely be picked up by a big pharma company, and its patents may end up being worth something eventually. It was delisted today as an empty shell company and is trading for a bit over 7 cents per share. Contrast UBX with NAGE. 1. We know NR works. 2. Our CEO is careful not to run out of money. 3. NAGE is in the green, with no debt, and a growing reserve. 4. NAGE has many pharma shots on goal. 5. NAGE (CDXC) once was flirting with being delisted. Not now.
